Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells

Background Wilms tumor (WT) is an embryonic kidney cancer, for which histone acetylation might be a therapeutic target. LBH589, a novel targeted agent, suppresses histone deacetylases in many tumors. This study investigated the antitumor activity of LBH589 in SK-NEP-1 and G401 cells. Methods SK-NEP-1 and G401 cell growth was assessed by CCK-8 and in nude mice experiments. Annexin V/propidium iodide staining followed by flow cytometry detected apoptosis in cell culture. Gene expressions of LBH589-treated tumor cells were analyzed using an Arraystar Human LncRNA Array. The Multi Experiment View cluster software analyzed the expression data. Differentially expressed genes from the cluster analyses were imported into the Ingenuity Pathway Analysis tool. Results LBH589 inhibited cell proliferation of SK-NEP-1 and G401 cells in a dose-dependent manner. Annexin V, TUNEL and Hochest 33342 staining analysis showed that LBH589-treated cells showed more apoptotic features compared with the control. LBH589 treatment inhibited the growth of SK-NEP-1 xenograft tumors in nude mice. Arraystar Human LncRNA Array analysis of genes and lncRNAs regulated by LBH589 identified 6653 mRNAs and 8135 lncRNAs in LBH589-treated SK-NEP-1 cells. The most enriched gene ontology terms were those involved in nucleosome assembly. KEGG pathway analysis identified cell cycle proteins, including CCNA2, CCNB2, CCND1, CCND2, CDK4, CDKN1B and HDAC2, etc. Ingenuity Pathway Analysis identified important upstream molecules: HIST2H3C, HIST1H4A, HIST1A, HIST1C, HIST1D, histone H1, histone H3, RPRM, HSP70 and MYC. Conclusions LBH589 treatment caused apoptosis and inhibition of cell proliferation of SK-NEP-1and G401 cells. LBH589 had a significant effect and few side effects on SK-NEP-1 xenograft tumors. Expression profiling, and GO, KEGG and IPA analyses identified new targets and a new “network” of genes responding to LBH589 treatment in SK-NEP-1 cells. RPRM, HSP70 and MYC may be important regulators during LBH589 treatment. Our results provide new clues to the proapoptotic mechanism of LBH589.

[1]  Xiao-Ming Yin,et al.  Analysis of Apoptosis , 2003 .

[2]  David M. Woods,et al.  The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity , 2013, Melanoma research.

[3]  A. Rossi,et al.  A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  S. Kügler,et al.  HDAC1 Regulates Fear Extinction in Mice , 2012, The Journal of Neuroscience.

[5]  A. Sandler,et al.  Pediatric malignancies: neuroblastoma, Wilm's tumor, hepatoblastoma, rhabdomyosarcoma, and sacroccygeal teratoma. , 2012, The Surgical clinics of North America.

[6]  R. Johnstone,et al.  New and emerging HDAC inhibitors for cancer treatment. , 2014, The Journal of clinical investigation.

[7]  P. Atadja,et al.  The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. , 2007, Blood.

[8]  F. Marano,et al.  The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype. , 2014, International journal of oncology.

[9]  P. Atadja,et al.  SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells , 2013, Cell Death and Disease.

[10]  Ping Zhu,et al.  Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. , 2004, Cancer cell.

[11]  A. Lane,et al.  Histone deacetylase inhibitors in cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Nishant Bhatta,et al.  LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/stat3/akt pathway , 2013, Molecular Cancer.

[13]  Kevin Girtman,et al.  SK‐NEP‐1 and Rh1 are Ewing family tumor lines , 2008, Pediatric blood & cancer.

[14]  V. Adam,et al.  Histone deacetylase inhibitors in cancer therapy. A review. , 2013, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[15]  K. Lillehei,et al.  Reprimo (RPRM) is a novel tumor suppressor in pituitary tumors and regulates survival, proliferation, and tumorigenicity. , 2012, Endocrinology.

[16]  A. Mai,et al.  Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 – 2013) , 2014, Expert opinion on therapeutic patents.

[17]  K. Yamashita,et al.  DNA Damage-Inducible Gene, Reprimo Functions as a Tumor Suppressor and Is Suppressed by Promoter Methylation in Gastric Cancer , 2013, Molecular Cancer Research.

[18]  C. Teng,et al.  A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCδ and E-cadherin , 2014, Oncotarget.

[19]  Xin Ma,et al.  LncRNAs Expression Signatures of Renal Clear Cell Carcinoma Revealed by Microarray , 2012, PloS one.

[20]  Y. Oda,et al.  Expression profile of class I histone deacetylases in human cancer tissues. , 2007, Oncology reports.

[21]  Barbara Hero,et al.  Histone Deacetylase 8 in Neuroblastoma Tumorigenesis , 2009, Clinical Cancer Research.

[22]  Yanhong Li,et al.  Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells , 2012, BMC Cancer.

[23]  Wenfang Xu,et al.  The development and potential clinical utility of biomarkers for HDAC inhibitors. , 2013, Drug discoveries & therapeutics.

[24]  Linda Z Sun,et al.  Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma , 2008, Leukemia & lymphoma.

[25]  Kang-Ping Lin,et al.  P21-Driven Multifusion Gene System for Evaluating the Efficacy of Histone Deacetylase Inhibitors by In Vivo Molecular Imaging and for Transcription Targeting Therapy of Cancer Mediated by Histone Deacetylase Inhibitor , 2014, The Journal of Nuclear Medicine.

[26]  S. Zhang,et al.  Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo. , 2014, International journal of oncology.

[27]  J. T. Caldwell,et al.  Panobinostat Synergistically Enhances the Cytotoxic Effects of Cisplatin, Doxorubicin or Etoposide on High-Risk Neuroblastoma Cells , 2013, PloS one.

[28]  P. Houghton,et al.  Evaluation of the Antitumor Efficacy, Pharmacokinetics, and Pharmacodynamics of the Histone Deacetylase Inhibitor Depsipeptide in Childhood Cancer Models In vivo , 2006, Clinical Cancer Research.

[29]  G. Jenkins,et al.  Reprimo 824 G>C and p53R2 4696 C>G single nucleotide polymorphisms and colorectal cancer: a case–control disease association study , 2008, International Journal of Colorectal Disease.

[30]  O. Larsson,et al.  The HDAC inhibitor LBH 589 enhances the anti-myeloma effects of the IGF-1 RTK inhibitor picropodophyllin , 2012 .

[31]  W. Weichert,et al.  Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo , 2008, Clinical Cancer Research.

[32]  Sheng-Tang Wu,et al.  The HDAC Inhibitor LBH589 Induces ERK-Dependent Prometaphase Arrest in Prostate Cancer via HDAC6 Inactivation and Down-Regulation , 2013, PloS one.

[33]  K. Anderson,et al.  Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia. , 2013, Blood.

[34]  HighWire Press.  The journal of neuroscience : the official journal of the Society for Neuroscience. , 1981 .

[35]  A. Gibson.  The European Society for Medical Oncology (ESMO) , 2019, Annals of Oncology.

[36]  Carlos Barrientos,et al.  Reprimo as a Potential Biomarker for Early Detection in Gastric Cancer , 2008, Clinical Cancer Research.

[37]  Hui Xie,et al.  Histone deacetylase inhibitors induce human renal cell carcinoma cell apoptosis through p-JNK activation. , 2013, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[38]  Yong Li,et al.  Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells , 2013, PloS one.

[39]  Xiaoyan Li,et al.  Progress of HDAC inhibitor panobinostat in the treatment of cancer. , 2014, Current drug targets.

[40]  Simon S. Jones,et al.  Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC , 2013, British journal of haematology.

[41]  S. Götze,et al.  Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells. , 2014, International journal of oncology.

[42]  J. Shim,et al.  The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma. , 2013, International journal of molecular medicine.

[43]  Hao Lin,et al.  Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells. , 2011, Taiwanese journal of obstetrics & gynecology.

[44]  Y. Mitani,et al.  Histone Acetylation and Gastrointestinal Carcinogenesis , 2003, Annals of the New York Academy of Sciences.

[45]  G. Adema,et al.  HDAC inhibitors and immunotherapy; a double edged sword? , 2014, Oncotarget.

[46]  T. Taniguchi,et al.  Reprimo, a New Candidate Mediator of the p53-mediated Cell Cycle Arrest at the G2 Phase* , 2000, The Journal of Biological Chemistry.

[47]  G. Bartsch,et al.  HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A , 2014, Molecular Cancer.

[48]  K. Bystricky,et al.  Activation of p21 by HDAC Inhibitors Requires Acetylation of H2A.Z , 2013, PloS one.

[49]  Z. Darżynkiewicz,et al.  Analysis of apoptosis by cytometry using TUNEL assay. , 2008, Methods.

[50]  Suk Woo Nam,et al.  Increased expression of histone deacetylase 2 is found in human gastric cancer , 2005, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[51]  E. D. Jacobsen,et al.  Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  O. Larsson,et al.  The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin , 2012, Clinical Cancer Research.

[53]  M. Socinski,et al.  Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer. , 2013, Anticancer research.

[54]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[55]  S. Filetti,et al.  Targeting histone deacetylase in thyroid cancer , 2013, Expert opinion on therapeutic targets.

[56]  Ming-Shiang Wu,et al.  HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells , 2011, PloS one.

[57]  M. Gessler,et al.  Retinoic acid pathway activity in wilms tumors and characterization of biological responses in vitro , 2011, Molecular Cancer.

[58]  N. Hukriede,et al.  HDAC inhibitors in kidney development and disease , 2012, Pediatric Nephrology.

[59]  H. Cai,et al.  HDAC as a therapeutic target for treatment of endometrial cancers. , 2014, Current pharmaceutical design.